Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials

• Published in: Hepatology (Baltimore, Md.) Vol. 68; no. 2; pp. 763 - 772
• Main Authors: Caussy, Cyrielle, Reeder, Scott B., Sirlin, Claude B., Loomba, Rohit
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.08.2018; Wiley-Blackwell
• Subjects: Alcohol use; Biomarkers; Biopsy; Cirrhosis; Clinical Trials as Topic; Drug development; Fatty liver; FDA approval; Hepatology; Humans; Intra-Abdominal Fat - diagnostic imaging; Life Sciences; Liver - diagnostic imaging; Liver - pathology; Liver cirrhosis; Liver diseases; Liver transplantation; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; NMR; Non-alcoholic Fatty Liver Disease - diagnostic imaging; Non-alcoholic Fatty Liver Disease - pathology; Nuclear magnetic resonance; United States > US; Gastroenterology & Hepatology; nonalcoholic steatohepatitis; magnitude-based mri; disease; fraction estimation; quantification; shift-encoded mri; magnetic-resonance elastography; flip-angle; obese subjects; hepatic steatosis
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.29797

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration–approved therapies for treating NASH. A major barrier for drug development in NASH is that treatment response assessment continues to require liver biopsy, which is invasive and interpreted subjectively. Therefore, there is a major unmet need for developing noninvasive, objective, and quantitative biomarkers for diagnosis and assessment of treatment response. Emerging data support the use of magnetic resonance imaging–derived proton density fat fraction (MRI‐PDFF) as a noninvasive, quantitative, and accurate measure of liver fat content to assess treatment response in early‐phase NASH trials. In this review, we discuss the role and utility, including potential sample size reduction, of MRI‐PDFF as a quantitative and noninvasive imaging‐based biomarker in early‐phase NASH trials. Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide.() NAFLD can be broadly classified into two categories: nonalcoholic fatty liver, which has a minimal risk of progression to cirrhosis, and nonalcoholic steatohepatitis (NASH), the more progressive form of NAFLD, which has a significantly increased risk of progression to cirrhosis.() Over the past two decades, NASH‐related cirrhosis has become the second leading indication for liver transplantation in the United States.() For these reasons, pharmacological therapy for NASH is needed urgently. Despite intensive investigations, there are currently no therapies for treating NASH that have been approved by the United States Food and Drug Administration.()